The market for therapies to treat severe fungal infections (SFIs) is poised for growth over the next decade. Increases in SFI-susceptible and drug-treated populations, changes in medical practice, and the launch of novel, safer, and broader-acting antifungals will fuel rapid changes in this market. Strategic Overview of Severe Fungal Infections is a new study from Decision Resources, Inc., that provides comprehensive analysis of the SFI market and the main drivers of sales growth in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We assess the individual patient populations at risk for SFIs (HIV/AIDS, chemotherapy, solid-organ transplant, and surgical) qualitatively and quantitatively, and forecast future trends that will impact the success of current and emerging antifungal therapeutics over a 1999-2009 study period.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

Assessing the trends in SFI incidence, treatment, and mortality is a complex undertaking. Drug-resistant pathogens are on the horizon, and will change the medical practice and survival landscape. Likewise, previously rare fungi are emerging as sources of human infections and posing new challenges for clinicians. Changes in the SFI-susceptible populations rest on fluctuations in the underlying patient populations, of which one of the most important is HIV/AIDS. The advent of highly active antiretroviral therapy (HAART) has dramatically lowered the chance of progression from HIV to AIDS, concomitantly decreasing the incidence of fungal infections in this population. However, potential resistance to HAART and the possible long-term toxicity of this therapy have broad implications for the resurgence of SFIs in this population.

The development and launch of novel antifungal therapeutics will change the landscape of the SFI market over the study period. Three novel azoles that offer improved potency and a wide spectrum of activity are in late-stage development: voriconazole (Pfizer's Vfend, UK-109,496), posaconazole (Schering-Plough's SCH-56592), and ravuconazole (Bristol-Myers Squibb's BMS- 207147). Physicians are anxiously anticipating the launch of a promising new class of agents, the candins: caspofungin (Merck's Cancidas, MK-0991), micafungin (Fujisawa's MK-463), and anidulafungin (Versicor's V-Echinocandin, LY-303,366). Aronex is developing Nyotran, a novel liposomal formulation of nystatin. In addition, an exciting class of protein synthesis inhibitors, the sordarins, are in preclinical development by Glaxo SmithKline.

Strategic Overview of Severe Fungal Infections is part of the Infectious Disease portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years.

Contact: Frank Sama, 781.487.3753 (telephone), 781.487.5750 (fax), or sama@dresources.com (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail).

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc, 781-487-3753,
sama@dresources.com

Angiotensin-Converting Enzyme (ACE) Inhibitors May Have a Significant Impact on the Atherosclerosis Marketplace, According to a Decision Resources Study

View Now